Literature DB >> 18234462

The detection limit of a Gd3+-based T1 agent is substantially reduced when targeted to a protein microdomain.

Kenjiro Hanaoka1, Angelo Josue M Lubag, Aminta Castillo-Muzquiz, Thomas Kodadek, A Dean Sherry.   

Abstract

Simple low molecular weight (MW) chelates of Gd(3+) such as those currently used in clinical MRI are considered too insensitive for most molecular imaging applications. Here, we evaluated the detection limit (DL) of a molecularly targeted low MW Gd(3+)-based T(1) agent in a model where the receptor concentration was precisely known. The data demonstrate that receptors clustered together to form a microdomain of high local concentration can be imaged successfully even when the bulk concentration of the receptor is quite low. A GdDO3A-peptide identified by phage display to target the anti-FLAG antibody was synthesized, purified and characterized. T(1-)weighted MR images were compared with the agent bound to antibody in bulk solution and with the agent bound to the antibody localized on agarose beads. Fluorescence competition binding assays show that the agent has a high binding affinity (K(D)=150 nM) for the antibody, while the fully bound relaxivity of the GdDO3A-peptide/anti-FLAG antibody in solution was a relatively modest 17 mM(-1) s(-1). The agent/antibody complex was MR silent at concentrations below approximately 9 microM but was detectable down to 4 microM bulk concentrations when presented to antibody clustered together on the surface of agarose beads. These results provided an estimate of the DLs for other T(1)-based agents with higher fully bound relaxivities or multimeric structures bound to clustered receptor molecules. The results demonstrate that the sensitivity of molecularly targeted contrast agents depends on the local microdomain concentration of the target protein and the molecular relaxivity of the bound complex. A model is presented, which predicts that for a molecularly targeted agent consisting of a single Gd(3+) complex with bound relaxivity of 100 mM(-1) s(-1) or, more reasonably, four tethered Gd(3+) complexes each having a bound relaxivity of 25 mM(-1) s(-1), the DL of a protein microdomain is approximately 690 nM at 9.4 T. These experimental and extrapolated DLs are both well below current literature estimates and suggests that detection of low MW molecularly targeted T(1) agents is not an unrealistic goal.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18234462      PMCID: PMC2483407          DOI: 10.1016/j.mri.2007.11.002

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  25 in total

1.  In vivo visualization of gene expression using magnetic resonance imaging.

Authors:  A Y Louie; M M Hüber; E T Ahrens; U Rothbächer; R Moats; R E Jacobs; S E Fraser; T J Meade
Journal:  Nat Biotechnol       Date:  2000-03       Impact factor: 54.908

2.  Magnetic resonance imaging detects a specific peptide-protein binding event.

Authors:  Luis M De León-Rodríguez; Alfonso Ortiz; Allison L Weiner; Shanrong Zhang; Zoltan Kovacs; Thomas Kodadek; A Dean Sherry
Journal:  J Am Chem Soc       Date:  2002-04-10       Impact factor: 15.419

3.  Development of a tumor-targeting MR contrast agent using the high-affinity folate receptor: work in progress.

Authors:  S D Konda; M Aref; M Brechbiel; E C Wiener
Journal:  Invest Radiol       Date:  2000-01       Impact factor: 6.016

4.  LHRH-conjugated magnetic iron oxide nanoparticles for detection of breast cancer metastases.

Authors:  Carola Leuschner; Challa S S R Kumar; William Hansel; Wole Soboyejo; Jikou Zhou; Josef Hormes
Journal:  Breast Cancer Res Treat       Date:  2006-06-03       Impact factor: 4.872

Review 5.  Targeting cells with MR imaging probes based on paramagnetic Gd(III) chelates.

Authors:  S Aime; A Barge; C Cabella; S Geninatti Crich; E Gianolio
Journal:  Curr Pharm Biotechnol       Date:  2004-12       Impact factor: 2.837

6.  Multilocus binding increases the relaxivity of protein-bound MRI contrast agents.

Authors:  Zhaoda Zhang; Matthew T Greenfield; Marga Spiller; Thomas J McMurry; Randall B Lauffer; Peter Caravan
Journal:  Angew Chem Int Ed Engl       Date:  2005-10-21       Impact factor: 15.336

Review 7.  Tissue-specific MR contrast agents.

Authors:  Hanns-Joachim Weinmann; Wolfgang Ebert; Bernd Misselwitz; Heribert Schmitt-Willich
Journal:  Eur J Radiol       Date:  2003-04       Impact factor: 3.528

8.  Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging.

Authors:  D A Sipkins; D A Cheresh; M R Kazemi; L M Nevin; M D Bednarski; K C Li
Journal:  Nat Med       Date:  1998-05       Impact factor: 53.440

9.  In vivo magnetic resonance detection of cancer by using multifunctional magnetic nanocrystals.

Authors:  Yong-Min Huh; Young-wook Jun; Ho-Taek Song; Sungjun Kim; Jin-sil Choi; Jae-Hyun Lee; Sarah Yoon; Kyung-sup Kim; Jeon-Soo Shin; Jin-Suck Suh; Jinwoo Cheon
Journal:  J Am Chem Soc       Date:  2005-09-07       Impact factor: 15.419

10.  Solid-phase synthesis of DOTA-peptides.

Authors:  Luis M De León-Rodriguez; Zoltan Kovacs; Gregg R Dieckmann; A Dean Sherry
Journal:  Chemistry       Date:  2004-03-05       Impact factor: 5.236

View more
  21 in total

1.  Strategies for the preparation of bifunctional gadolinium(III) chelators.

Authors:  Luca Frullano; Peter Caravan
Journal:  Curr Org Synth       Date:  2011-08-01       Impact factor: 1.975

Review 2.  In vivo imaging of molecular targets and their function in endocrinology.

Authors:  Joanna E Burdette
Journal:  J Mol Endocrinol       Date:  2008-06       Impact factor: 5.098

3.  Reporter protein-targeted probes for magnetic resonance imaging.

Authors:  Renee C Strauch; Daniel J Mastarone; Preeti A Sukerkar; Ying Song; Jonathan J Ipsaro; Thomas J Meade
Journal:  J Am Chem Soc       Date:  2011-09-26       Impact factor: 15.419

Review 4.  Molecular magnetic resonance contrast agents for the detection of cancer: past and present.

Authors:  Alexei Bogdanov; Mary L Mazzanti
Journal:  Semin Oncol       Date:  2011-02       Impact factor: 4.929

5.  Influence of molecular parameters and increasing magnetic field strength on relaxivity of gadolinium- and manganese-based T1 contrast agents.

Authors:  Peter Caravan; Christian T Farrar; Luca Frullano; Ritika Uppal
Journal:  Contrast Media Mol Imaging       Date:  2009 Mar-Apr       Impact factor: 3.161

6.  Polymeric PARACEST agents for enhancing MRI contrast sensitivity.

Authors:  Yunkou Wu; Youfu Zhou; Olivier Ouari; Mark Woods; Piyu Zhao; Todd C Soesbe; Garry E Kiefer; A Dean Sherry
Journal:  J Am Chem Soc       Date:  2008-09-26       Impact factor: 15.419

7.  Molecular imaging without radiopharmaceuticals?

Authors:  John C Gore; Thomas E Yankeelov; Todd E Peterson; Malcolm J Avison
Journal:  J Nucl Med       Date:  2009-05-14       Impact factor: 10.057

Review 8.  Design of a novel class of protein-based magnetic resonance imaging contrast agents for the molecular imaging of cancer biomarkers.

Authors:  Shenghui Xue; Jingjuan Qiao; Fan Pu; Mathew Cameron; Jenny J Yang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2013-01-17

9.  Synthesis and Evaluation of Gd(III) -Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen.

Authors:  Sangeeta Ray Banerjee; Ethel J Ngen; Matthew W Rotz; Samata Kakkad; Ala Lisok; Richard Pracitto; Mrudula Pullambhatla; Zhengping Chen; Tariq Shah; Dmitri Artemov; Thomas J Meade; Zaver M Bhujwalla; Martin G Pomper
Journal:  Angew Chem Int Ed Engl       Date:  2015-07-23       Impact factor: 15.336

10.  A new gadolinium-based MRI zinc sensor.

Authors:  Ana C Esqueda; Jorge A López; Gabriel Andreu-de-Riquer; José C Alvarado-Monzón; James Ratnakar; Angelo J M Lubag; A Dean Sherry; Luis M De León-Rodríguez
Journal:  J Am Chem Soc       Date:  2009-08-19       Impact factor: 15.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.